The Psychological Risks Associated With the Non-medical Switch From Biologics to Biosimilars.
作者信息
Mazzoni Davide, Vener Claudia, Mazzocco Ketti, Monzani Dario, Pravettoni Gabriella
机构信息
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Applied Research Division for Cognitive and Psychological Science, European Institute of Oncology IRCCS, Milan, Italy.
出版信息
Front Psychol. 2021 Jan 27;12:605643. doi: 10.3389/fpsyg.2021.605643. eCollection 2021.
Abstract
摘要
相似文献
1
The Psychological Risks Associated With the Non-medical Switch From Biologics to Biosimilars.
Front Psychol. 2021 Jan 27;12:605643. doi: 10.3389/fpsyg.2021.605643. eCollection 2021.
2
The Clinical Implications of Nocebo Effects for Biosimilar Therapy.
Front Pharmacol. 2019 Nov 29;10:1372. doi: 10.3389/fphar.2019.01372. eCollection 2019.
3
Biosimilars: complements and comments on the recent statement of the SFR and CRI. Comment on: "Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI)." Schaeverbeke et al. Joint Bone Spine 2018;95:399-402.
Joint Bone Spine. 2019 Mar;86(2):287-288. doi: 10.1016/j.jbspin.2018.10.009. Epub 2018 Oct 27.
4
The nocebo effect: a clinical challenge in the era of biosimilars.
Expert Rev Clin Immunol. 2018 Sep;14(9):739-749. doi: 10.1080/1744666X.2018.1512406. Epub 2018 Aug 30.
5
Patients' information and perspectives on biosimilars in rheumatology: A French nation-wide survey.
Joint Bone Spine. 2019 Jul;86(4):491-496. doi: 10.1016/j.jbspin.2019.01.001. Epub 2019 Jan 16.
6
Biosimilars in oncology: from development to clinical practice.
Semin Oncol. 2014 Apr;41 Suppl 3:S3-S12. doi: 10.1053/j.seminoncol.2014.03.008. Epub 2014 Mar 13.
7
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.
Rheumatol Int. 2016 May;36(5):613-25. doi: 10.1007/s00296-016-3444-0. Epub 2016 Feb 27.
8
Biosimilars for the treatment of psoriasis.
Expert Opin Biol Ther. 2019 Oct;19(10):993-1000. doi: 10.1080/14712598.2019.1636963. Epub 2019 Jul 1.
9
Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review.
Clin Ther. 2019 Jan;41(1):155-173.e13. doi: 10.1016/j.clinthera.2018.11.002. Epub 2018 Dec 11.
10
DISCONTINUATION RATES FOLLOWING A SWITCH FROM A REFERENCE TO A BIOSIMILAR BIOLOGIC IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS.
Arq Gastroenterol. 2020 Jul-Sep;57(3):232-243. doi: 10.1590/S0004-2803.202000000-45.
引用本文的文献
1
Stakeholder perspectives on the sustainability of the United States biosimilars market.
J Manag Care Spec Pharm. 2024 Oct;30(10):1065-1072. doi: 10.18553/jmcp.2024.24104. Epub 2024 Jul 16.
2
Consensus-Based Overarching Principles and Recommendations on the Use of Biosimilars in the Treatment of Inflammatory Arthritis in the Gulf Region.
BioDrugs. 2024 May;38(3):449-463. doi: 10.1007/s40259-023-00642-1. Epub 2024 Feb 25.
本文引用的文献
1
One-year results after transitioning from etanercept originator to biosimilar in a setting promoting shared decision-making in rheumatology.
Rheumatol Adv Pract. 2020 Aug 6;4(2):rkaa042. doi: 10.1093/rap/rkaa042. eCollection 2020.
2
Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars.
Pharmacoepidemiol Drug Saf. 2020 Jul;29(7):757-769. doi: 10.1002/pds.4809. Epub 2019 Jul 12.
3
The non-medical switching of prescription medications.
Postgrad Med. 2019 Jun;131(5):335-341. doi: 10.1080/00325481.2019.1618195. Epub 2019 May 29.
4
Nurses are Critical in Aiding Patients Transitioning to Biosimilars in Inflammatory Bowel Disease: Education and Communication Strategies.
J Crohns Colitis. 2019 Feb 1;13(2):259-266. doi: 10.1093/ecco-jcc/jjy150.
5
Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent.
BioDrugs. 2018 Oct;32(5):397-404. doi: 10.1007/s40259-018-0306-1.
6
The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies.
J Manag Care Spec Pharm. 2018 Oct;24(10):952-959. doi: 10.18553/jmcp.2018.24.10.952.
7
Psychobiological Mechanisms of Placebo and Nocebo Effects: Pathways to Improve Treatments and Reduce Side Effects.
Annu Rev Psychol. 2019 Jan 4;70:599-625. doi: 10.1146/annurev-psych-010418-102907. Epub 2018 Aug 15.
8
Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect.
Rheumatol Ther. 2017 Dec;4(2):209-218. doi: 10.1007/s40744-017-0085-z. Epub 2017 Oct 14.
9
Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: A survey of physicians and pharmacists in Ireland.
Regul Toxicol Pharmacol. 2017 Aug;88:252-261. doi: 10.1016/j.yrtph.2017.06.013. Epub 2017 Jun 27.
10
Value as the key concept in the health care system: how it has influenced medical practice and clinical decision-making processes.
J Multidiscip Healthc. 2017 Mar 21;10:101-106. doi: 10.2147/JMDH.S122383. eCollection 2017.
Zotero 插件